**EMBARGOED FOR RELEASE: 11 A.M. (ET) TUESDAY, MAY 16, 2017**

Media Advisory: To contact Timothy E. McAlindon, D.M., M.P.H., email Jeremy Lechan at [jlechan@tuftsmedicalcenter.org](mailto:jlechan@tuftsmedicalcenter.org).

**To place an electronic embedded link to this study in your story** This link will be live at the embargo time: <http://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2017.5283>

***JAMA***

**Findings Do Not Support Steroid Injections for Knee Osteoarthritis**

Among patients with knee osteoarthritis, an injection of a corticosteroid every three months over two years resulted in significantly greater cartilage volume loss and no significant difference in knee pain compared to patients who received a placebo injection, according to a study published by *JAMA*.

Symptomatic knee osteoarthritis was estimated to affect more than 9 million individuals in the United States in 2005 and is a leading cause of disability and medical costs. Treatments for osteoarthritis are primarily prescribed to reduce symptoms, with no interventions known to influence structural progression. Synovitis (inflammation of a membrane that lines the joints) is common and is associated with progression of structural characteristics of knee osteoarthritis. Intra-articular corticosteroids (an injection in the joint) could reduce cartilage damage associated with synovitis but might have adverse effects on cartilage and bone.

Timothy E. McAlindon, D.M., M.P.H., of Tufts Medical Center, Boston, and colleagues randomly assigned 140 patients with symptomatic knee osteoarthritis with features of synovitis to injections in the joint with the corticosteroid triamcinolone (n = 70) or saline (n = 70) every 12 weeks for two years. The researchers found that injections with triamcinolone resulted in significantly greater cartilage volume loss than did saline (average change in cartilage thickness of -0.21 mm vs -0.10 mm) and no significant difference on measures of pain. The saline group had three treatment-related adverse events compared with five in the triamcinolone group.

Several limitations of the study are noted in the article, including that any transient benefit on pain ending within the 3-month period between each injection could have been missed by methods used in the study.

“These findings do not support this treatment for patients with symptomatic knee osteoarthritis,” the authors write.

For more details and to read the full study, please visit the For The Media [website](http://media.jamanetwork.com/).

(doi:10.1001/jama.2017.5283)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

# # #

**For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email** [mediarelations@jamanetwork.org](mailto:mediarelations@jamanetwork.org)**.**